Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations

References

• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes—2017. Diabetes Care. 2017;40(Suppl 1):S1–S135.
   PubMedGoogle Scholar
• Juarez DT, Ma C, Kumasaka A, et al. Failure to reach target glycated A1c levels among patients with diabetes who are adherent to their antidiabetic medication. Popul Health Manag. 2014;17:218–223.
   PubMed Web of Science ®Google Scholar
• Shah PK, Mudaliar S, Chang AR, et al. Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:505–510.
   PubMed Web of Science ®Google Scholar
• Davidson JA. Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy. Postgrad Med. 2015;127:827–841.
   PubMed Web of Science ®Google Scholar
• Mathieu C, Rodbard HW, Cariou B, et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab. 2014;16:636–644.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Guerci B, Hanefeld M, et al. Prandial options to advance basal insulin glargine therapy: testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: the GetGoal Duo-2 trial. Diabetes Care. 2016;39:1318–1328.
   PubMed Web of Science ®Google Scholar
• Lin J, Lingohr-Smith M, Fan T. Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US. Clinicoecon Outcomes Res. 2017;9:19–29.
   PubMed Web of Science ®Google Scholar
• Xultophy® 100/3.6 (insulin degludec and liraglutide injection), for subcutaneous use: US prescribing information. Plainsboro, NJ: Novo Nordisk Inc. November 2016. Available from: www.novo-pi.com/xultophy10036.pdf
   Google Scholar
• Xultophy (insulin degludec/liraglutide): European public assessment report. London: European Medicines Agency; 2015 December 11. [cited 2017 Oct]. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002647/human_med_001802.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Soliqua® 100/33 (insulin glargine and lixisenatide injection), for subcutaneous use: US prescribing information. Bridgewater, NJ: Sanofi-aventis US LLC. August 2017. Available from: products.sanofi.us/soliqua100-33/soliqua100-33.pdf
   Google Scholar
• Suliqua (insulin glargine/lixisenatide): European public assessment report. London: European Medicines Agency; 2017 March 30. [cited 2017 Oct]. Available from www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004243/human_med_002064.jsp&mid=WC0b01ac058001d124
   Google Scholar
• DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes. Diabetes. 2009;58:773–795.
   PubMed Web of Science ®Google Scholar
• Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med. 2006;119(5 Suppl 1):S10–S16.
   PubMed Web of Science ®Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728–742.
   PubMed Web of Science ®Google Scholar
• Anderson AL, Trujillo JM. Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness. Ther Adv Chronic Dis. 2016;7(1):4–17.
   PubMed Web of Science ®Google Scholar
• Valentine V, Goldman J, Shubrook JH. Rationale for, initiation and titration of the basal insulin/GLP-1RA fixed-ratio combination products, IDegLira and IGlarLixi, for the management of type 2 diabetes. Diabetes Ther. 2017;8:739–752.
   PubMed Web of Science ®Google Scholar
• Adlyxin® (lixisenatide) injection, for subcutaneous use: US prescribing information. Bridgewater, NJ: Sanofi-aventis US LLC; July 2016. Available from: products.sanofi.us/adlyxin/adlyxin.pdf
   Google Scholar
• Sanofi. Lixisenatide and iGlarLixi (insulin glargine/lixisenatide fixed-ratio combination) for the treatment of type 2 diabetes mellitus. Briefing document for Endocrinologic and Metabolic Drugs Advisory Committee meeting. Silver Spring, MD: Food and Drug Administration; 2016 May 25. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM502559.pdf
   Google Scholar
• Buse JB, Vilsbøll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014;37:2926–2933.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Rosenstock J, Wysham C, et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin plus metformin: the LixiLan-L randomized trial. Diabetes Care. 2016;39:1972–1980.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care. 2016;39:2026–2035.
   PubMed Web of Science ®Google Scholar
• García-Pérez LE, Álvarez M, Dilla T, et al. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4:175–194.
   PubMed Web of Science ®Google Scholar
• Blonde L, Bailey TS, Chao J, et al. Characteristics and glycemic outcomes of T2D patients (pts) titrated to 60 U/day with insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) vs. insulin in the LixiLan-L Trial. In: Abstracts of American Diabetes Association 77th Scientific Sessions. San Diego, CA: June 9–13 2017. Diabetes 2017;66(Suppl1): A294[abstract 1107-P].
   Google Scholar
• Frias J, Hurst W, Newton J, et al. Impact of lixisenatide (LIXI) dose range on clinical outcomes with fixed-ratio combination (FRC) iGlarLixi in patients with T2D. In: Abstracts of American Diabetes Association 77th Scientific Sessions. San Diego, CA: June 9–13 2017. Diabetes. 2017;66(Suppl1): A291[abstract 1100-P].
   Google Scholar
• Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2:885–893.
   PubMed Web of Science ®Google Scholar
• Harris SB, Kapor J, Lank CN, et al. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician. 2010;56:418–424.
   PubMed Web of Science ®Google Scholar
• Victoza® (liraglutide) injection, for subcutaneous use: US prescribing information. Plainsboro, NJ: Novo Nordisk Inc; August 2017 [cited 2017 Oct]. Available from: www.novo-pi.com/victoza.pdf
   Google Scholar
• Blackberry ID, Furler JS, Ginnivan LE, et al. An exploratory trial of insulin initiation and titration among patients with type 2 diabetes in the primary care setting with retrospective continuous glucose monitoring as an adjunct: INITIATION study protocol. BMC Fam Pract. 2014;3:82.
   Web of Science ®Google Scholar